Oxford Biomedica
 | |
| Company type | Public company |
|---|---|
| Industry | Pharmaceutical industry |
| Founded | 1995 |
| Headquarters | Oxford |
Key people | Frank Mathias (CEO) |
| Revenue |  £89.5 million (2023)[1] |
| £(184.2) million (2023)[1] | |
| £(184.2) million (2023)[1] | |
| Website | https://oxb.com/ |
Oxford Biomedica is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange.[2]
History
[edit]The company was established in 1995 as a spin out from the University of Oxford.[3] It was the subject of an initial public offering on the Alternative Investment Market in 1996.[4]
In 2018, Oxford Biomedica's gene therapy for Parkinson's disease became the subject of a commercialization deal with Axovant Sciences.[5]
In May 2019, the company announced an investment by Novo Holdings for a stake of 10.1% in Oxford Biomedica, totalling $55 million (USD) to develop its gene therapy technology.[6] The firm had already established collaborations with Sanofi, Novartis and other groups to provide lentiviral vector manufacturing.[7]
In November 2019, Microsoft announced a partnership with Oxford Biomedica to improve the next generation of cell and gene delivery technology using the cloud and machine learning, contributing large data sets for analysis via the Microsoft Azure intelligent cloud platform to develop in-silico models and novel algorithms to help provide long-term and curative treatments for a wide range of diseases.[8]
In December 2019, the company announced that it has extended its commercial supply agreement with Novartis for the manufacture of lentiviral vectors for the Novartis CAR-T portfolio including five lentiviral vectors for CAR-T products, which builds on the existing three-year commercial supply agreement signed by the parties in July 2017.[9]
In April 2020, Oxford Biomedica announced that the company had joined a Consortium led by the Jenner Institute, Oxford University, to develop and manufacture a vaccine for COVID-19: ChAdOx1 nCov-19.[10] This is one of the vaccines currently being deployed under a conditional authorisation.[11][12]
In September 2023, it was announced Oxford Biomedica had acquired the Illkirch-Graffenstaden-headquartered, viral vectors drug product manufacturing services company, ABL Europe from the Mérieux Institute.[13]
References
[edit]- ^ a b c "Annual Results 2023". Oxford Biomedica. Retrieved 29 April 2024.
- ^ "FTSE UK Index Series: Annual Review June 2020". 3 June 2020. Archived from the original on 3 June 2020. Retrieved 3 June 2020.
- ^ Hoover's | A D&B Company. Hoovers.com.
- ^ Owen, Geoffrey; Hopkins, Michael M. (2016). Science, the State and the City: Britain's Struggle to Succeed in Biotechnology. Oxford University Press. p. 174. ISBN 978-0198728009.
- ^ Cookson, Clive (6 June 2018). "Oxford Biomedica seals $842m Parkinson's therapy deal with Axovant". Retrieved 27 June 2018.
- ^ Smith, Jonathan (29 May 2019). "€60M Investment to Boost Oxford Biomedica's Gene and Cell Therapies". Labiotech.eu. Retrieved 13 March 2020.
- ^ "Plenty of choice remains for buyers of gene therapy". Evaluate.com. 20 December 2019. Retrieved 26 March 2020.
- ^ Rut, Andrew (28 October 2019). "Transforming the landscape". PharmaTimes. Retrieved 4 March 2020.
- ^ "Oxford Biomedica extends lentiviral deal with Swiss giant". Phara Letter. 19 December 2019. Retrieved 3 June 2020.
- ^ "Could the Oxford University/AstraZeneca COVID-19 Vaccine End the Pandemic?". 2 July 2020. Retrieved 25 June 2020.
- ^ "Oxford Biomedica joins consortium for promising COVID-19 vaccine". Pharma Times. 8 April 2020. Retrieved 3 June 2020.
- ^ "Oxford Biomedica earns U.K. nod for 4th manufacturing suite to boost COVID-19 production". Fierce Pharma. 6 October 2020. Retrieved 8 May 2021.
- ^ "Oxford Biomedica acquires ABL Europe". The Business Magazine. 28 September 2023. Retrieved 28 September 2023.
